Lv41
428 积分 2021-01-23 加入
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
41分钟前
已完结
Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study
2小时前
已关闭
Consensus on standardized later-line systemic therapy for hepatocellular carcinoma
7天前
已完结
The future of blood-based biomarkers in liver cancer
7天前
已完结
A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study
12天前
已关闭
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
12天前
已完结
Systemic therapy of biliary tract cancer: The road to personalised strategies
18天前
已完结
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial
21天前
已完结
Influence of Efgartigimod on Curative Efficacy and Inflammation Factors of Patients with Long Segmental Myelitis
28天前
已完结
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
2个月前
已完结
皖公网安备34019202002308
